Sensei Biotherapeutics (SNSE) CEO converts Series B preferred into 761,428 common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sensei Biotherapeutics, Inc. President and CEO Anand Kiran Parikh converted preferred shares received in a merger into common stock. He acquired 761,428 shares of Common Stock through the conversion of 761.428 shares of Series B Preferred Stock, which are convertible into 1,000 common shares each with no expiration date. The Series B Preferred Stock had been issued as consideration when Faeth Holdings Therapeutics, Inc. common stock was converted into the right to receive these preferred shares at the closing of a multi‑step merger involving Faeth and its holding entities.
Positive
- None.
Negative
- None.
Insights
CEO converts merger-related preferred stock into common shares, a non-cash structural change.
The reporting person, Sensei Biotherapeutics’ President and CEO Anand Kiran Parikh, converted 761.428 shares of Series B Preferred Stock into 761,428 shares of Common Stock. The filing describes this as a conversion of a derivative security, not an open-market purchase or sale.
The footnotes explain that each Series B share is convertible into 1,000 common shares with no expiration date, and that these preferred shares were issued as consideration in a merger involving Faeth Holdings Therapeutics, Inc. All 761.428 preferred shares shown here were converted, leaving no remaining Series B position in this filing.
This is effectively a structural step that turns merger-related preferred equity into common equity, with no cash changing hands. The transaction does not indicate discretionary buying or selling by the CEO, so its informational value for equity sentiment is limited and best viewed as administrative merger cleanup.
Insider Trade Summary
761.428 shares exercised/converted
Mixed
2 txns
Insider
Parikh Anand Kiran
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock | 761.428 | $0.00 | -- |
| Conversion | Common Stock | 761,428 | $0.00 | -- |
Holdings After Transaction:
Series B Preferred Stock — 0 shares (Direct, null);
Common Stock — 761,428 shares (Direct, null)
Footnotes (1)
- Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date. Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger"). Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock.
Key Figures
Common shares acquired: 761,428 shares
Series B Preferred converted: 761.428 shares
Conversion ratio: 1,000 common shares per Series B share
+3 more
6 metrics
Common shares acquired
761,428 shares
Common Stock received via derivative conversion on June 15, 2026
Series B Preferred converted
761.428 shares
Series B Preferred Stock converted into Common Stock
Conversion ratio
1,000 common shares per Series B share
Set in Certificate of Designation; no expiration date
Transaction price per share
$0.0000
Reported for both Common Stock and Series B Preferred in this conversion
Common shares held after transaction
761,428 shares
Total Common Stock directly owned after conversion
Derivative exercises in filing
1 transaction, 761.428 shares
Exercise/convert of derivative security per transactionSummary
Key Terms
Series B Preferred Stock, Certificate of Designation, Agreement and Plan of Merger, Merger, +1 more
5 terms
Series B Preferred Stock financial
"each share of Series B Preferred Stock is convertible into 1,000 shares"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Certificate of Designation regulatory
"conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
Agreement and Plan of Merger regulatory
"Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement")"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger financial
"such mergers, the "Merger""
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
wholly owned subsidiary financial
"with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
FAQ
What did Sensei Biotherapeutics (SNSE) CEO Anand Kiran Parikh report in this Form 4?
He reported converting 761.428 shares of Series B Preferred Stock into 761,428 shares of Common Stock. The transaction is classified as a conversion of a derivative security, not a market trade, so it reflects restructuring of his equity rather than new buying or selling activity.
What is the conversion ratio of Sensei Biotherapeutics’ Series B Preferred Stock into common stock?
Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock. This ratio is set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock and the shares have no stated expiration date for the conversion right.
Does the CEO still hold any Series B Preferred Stock of Sensei Biotherapeutics after this transaction?
According to the reported figures, his Series B Preferred Stock holding associated with this transaction is reduced to zero. The derivative line for 761.428 Series B shares shows a post‑transaction balance of 0.0000, indicating that all those preferred shares were converted into common stock.